OPR - Delayed Quote • USD CNTA Jul 2024 7.500 put (CNTA240719P00007500) Follow 1.5500 0.0000 (0.00%) At close: January 22 at 12:43 PM EST Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for CNTA240719P00007500 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: CNTA Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024 Centessa Pharmaceuticals PLC (CNTA) Earnings: A Detailed Look at Q4 and Full-Year 2023 Results Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 Centessa Pharmaceuticals PLC Chief People Officer Sells Company Shares 7 Biotech Stocks Ready to Ride the Sector’s Resurgence Private equity firms who have a significant stake must be disappointed along with institutions after Centessa Pharmaceuticals plc's (NASDAQ:CNTA) market cap dropped by US$139m Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics
